The Starpharma Holdings Limited (ASX: SPL) share price was up 5.52% at the time of writing to $1.72. This came after the company announced a funding award to develop a COVID-19 nasal spray.
What was in the announcement?
Starphama said it had been awarded $1 million in funding from the Federal Government’s Medical Research Future Fund to develop a nasal spray for the treatment of COVID-19. The nasal spray would utilise its proprietary dendrimer, SPL7013.
The company said its patented SPL7013 nasal spray had the potential to prevent both acquisition and transmission of SARS-CoV-2. In addition, its broad spectrum antiviral activity could also play a role for other respiratory viruses and preparedness for future pandemics. SARS-CoV-2 is the virus that causes COVID-19.
The product could be used as an additional line of defence in combination with personal protective equipment. It would have applications for the general public including frontline workers such as doctors and nurses along with those exposed to crowded and high risk environments including public transport, airlines and aged care.
Starpharma said that since the SPL7013 development program started in April, the nasal spray has been reformulated into several formulations and a manufacturer identified. In addition, pilot manufacturing has been undertaken and work has started on compiling regulatory documentation for submission. Additionally, the company is in confidential commercial discussions with interested pharmaceutical companies in a number of geographic markets.
Starpharma CEO Dr Jackie Fairley said the funding award to develop Starphama’s program recognised “its near term potential and the global relevance of the SPL7013 COVID-19 nasal spray”.
About the Starpharma share price
Starpharma is a biotechnology company that develops and licenses treatments for various common health problems. It has agreements with a number of pharmaceutical giants and has been listed on the ASX since 2000.
The Starpharma share price is up 177.4% since its 52-week low of 62 cents. It has returned 40.98% since the beginning of the year. The Starpharma share price is up 49.57% since this time last year.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Why Lendlease, Redbubble, SeaLink, & Starpharma shares are pushing higher
- Starpharma share price rockets to record high on DEP remdesivir COVID-19 news
- Starpharma share price rockets to 52-week high on full year update
- Starpharma share price bolts 14% on COVID-19 nasal spray
- The Starpharma share price jumps on new partnership deal
Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Starpharma share price jumps 5% on funding for COVID-19 nasal spray appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2EVwSZ8
Leave a Reply